Results based on Statistical Enterprises Results by fields of operation

Business Sector Biotechnology indicators by company size.

Units:specified in variables

Select values to consult
- Main variables
  Values that contain
  
  Selected:67
  
  Total:67
- No. of employees
  Values that contain
  
  Selected:3
  
  Total:3

Choose format of the table

	No. of employees
Main variables	.	.	.
	.	.	.
	.	.	.

Decimals to show:

Notes
- 1) '.'=numeric piece of data equal to zero not resulting from rounding
  
  FTE: Full Time Equivalent

Total: 0seriesy 0cells

Source:National Statistics Institute

No. of companies carrying out R&D in Biotechnology
%Companies according to biotechnology used: Genetic code
%Companies according to biotechnology used: Functional units
%Companies according to biotechnology used: Cellular and tissue culturing and engineering
%Companies according to biotechnology used: Bioprocesses
%Companies according to biotechnology used: Sub-cellular organisms
%Companies according to biotechnology used: Bio-computing
%Companies according to biotechnology used: Nanobiotechnology
%Companies according to biotechnology used: Other
Companies in which biotechnology activities are: Main and/or exclusive
Companies in which biotechnology activities are: A secondary line of business
Companies in which biotechnology activities are: A tool necessary for production
%Company by field(s) of ultimate application of biotechnology use: Human Health
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture
%Company by field(s) of ultimate application of biotechnology use: Food products
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production
%Company by field(s) of ultimate application of biotechnology use: Environment
%Company by field(s) of ultimate application of biotechnology use: Industry
Personnel in R&D in biotechnology (no. of persons)
Personnel in R&D in biotechnology (no. of persons): Research personnel
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel
Personnel in R&D in biotechnology (no. of persons). Women
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel
Personnel in R&D in biotechnology (FTE)
Personnel in R&D in biotechnology (FTE): Research personnel
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel
Personnel in R&D in biotechnology (FTE). Women
Personnel in R&D in biotechnology (FTE). Women: Research personnel
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel
Internal expenditure on R&D (thousands of euros)
1) By nature of the expense: Current expenses
1.1) Remuneration to research personnel
1.2) Remuneration to technical and auxiliary personnel
1.3) Other current expenses
2) By nature of the expense: Capital expenses
2.1) Land and buildings
2.2) Equipment and instruments
2.3) Acquisition of specific R&D software
2.4) Otros productos de propiedad intelectual específicos para I+D
1.1) By origin of the funds: Own funds
1.2) By origin of the funds: From companies
1.3) By origin of the funds: Public Administration funds
1.4) By origin of the funds: From Universities
1.5) By origin of the funds: From non profit private institutions
1.6) By origin of the funds: Foreign funds
Purchase of R&D services in biotechnology (thousands of euros)
Purchase of R&D services in biotechnology (thousands of euros): In Spain
Purchase of R&D services in biotechnology (thousands of euros): Abroad
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting
% Companies with income of an international origin related to biotechnological activities
% Turnover representing income of an international origin related to biotechnological activities
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain
% Income of an international origin related with activities according to the classification: Operating source abroad
% Income of an international origin related with activities according to the classification: Other

Fewer than 250 employees
250 or more employees
Total 2021